SPAI Safe Pro (SPAI) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0002011208
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
What the filings say about SPAI
Insiders, 180 days
-$4.0M net sold
1 seller · 0% of sales under a 10b5-1 plan
Safe Pro insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Safe Pro Group Inc. insiders sold a net $4.0M of stock across 1 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 26.7% of the 3,749,058 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO ERDBERG DANIYEL sold about $4.0M of SPAI on Sep 9, 2026, the largest insider sale at the company on our record; 10 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.0M over 180 days
-$4.0M over 90 days · -$4.0M of it by a 10%+ holder
below 75% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 85% of Medical Devices
Revenue
-72.0% year over year
below 96% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
$2.3M repurchased, FY to 2026-06-30
below 83% of Medical Devices
Short interest
4.5% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 56% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SPAI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SPAI: institutional holders (13F)
13F holdings, latest reported quarter
563,837 sh
$2.4M
306,735 sh
$1.3M
230,500 sh
$998.1K
147,046 sh
$637.0K
139,551 sh
$604.3K
Congress trades in SPAI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SPAI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SPAI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$191.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.8K position · as of 2026-06-30
0.0%
T. Rowe Price Extended Equity Market Index Fund
$66.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$416.8K position · as of 2026-05-31
0.0%
Victory Extended Market Index Fund
$5.8K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$633.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $4.0M sold by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SPAI financials
Revenue growth
-72.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SPAI
| FY Dec 2025 | $606.7K |
| FY Dec 2024 | $2.2M |
| FY Dec 2023 | n/a |
| Jun 2026 | $1.3M |
| Mar 2026 | $1.2M |
| Dec 2025 | $227.7K |
| Sep 2025 | $101.4K |
| Jun 2025 | $92.8K |
| Mar 2025 | $184.8K |
| Dec 2024 | $887.8K |
| Sep 2024 | $330.8K |
At each fiscal year end
Single quarter
Net margin, TTM
-500.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SPAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | -342.5% |
| FY Dec 2023 | n/a |
| Jun 2026 | -237.9% |
| Mar 2026 | -228.9% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -155.9% |
| Sep 2024 | -1,114% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$8.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SPAI
| FY Dec 2025 | -$6.3M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | -$2.9M |
| Mar 2026 | -$1.2M |
| Dec 2025 | -$2.7M |
| Sep 2025 | -$1.6M |
| Jun 2025 | -$1.0M |
| Mar 2025 | -$960.0K |
| Dec 2024 | -$1.0M |
| Sep 2024 | -$1.9M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity SPAI
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.04x |
| FY Dec 2023 | n/a |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.06x |
| Mar 2025 | 0.06x |
| Dec 2024 | 0.04x |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-56.76x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt SPAI
| FY Dec 2025 | -42.58x |
| FY Dec 2024 | -28.05x |
| FY Dec 2023 | n/a |
| Jun 2026 | -56.76x |
| Mar 2026 | -44.20x |
| Dec 2025 | -42.58x |
| Sep 2025 | -31.37x |
| Jun 2025 | -33.70x |
| Mar 2025 | -30.61x |
| Dec 2024 | -28.05x |
| Sep 2024 | -22.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-198.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SPAI
| FY Dec 2025 | -132.7% |
| FY Dec 2024 | -262.9% |
| FY Dec 2023 | n/a |
| Jun 2026 | -198.2% |
| Mar 2026 | -145.6% |
| Dec 2025 | -132.7% |
| Sep 2025 | -193.7% |
| Jun 2025 | -706.7% |
| Mar 2025 | -594.1% |
| Dec 2024 | -262.9% |
| Sep 2024 | -318.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-168.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SPAI
| FY Dec 2025 | -119.0% |
| FY Dec 2024 | -177.3% |
| FY Dec 2023 | n/a |
| Jun 2026 | -168.8% |
| Mar 2026 | -128.8% |
| Dec 2025 | -119.0% |
| Sep 2025 | -161.8% |
| Jun 2025 | -333.9% |
| Mar 2025 | -278.0% |
| Dec 2024 | -177.3% |
| Sep 2024 | -191.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SPAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-199.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SPAI
| FY Dec 2025 | -132.7% |
| FY Dec 2024 | -235.7% |
| FY Dec 2023 | n/a |
| Jun 2026 | -199.5% |
| Mar 2026 | -146.4% |
| Dec 2025 | -132.7% |
| Sep 2025 | -177.3% |
| Jun 2025 | -627.0% |
| Mar 2025 | -357.9% |
| Dec 2024 | -235.7% |
| Sep 2024 | -229.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SPAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no cash line filed
Enterprise value SPAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-12.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield SPAI
| FY Dec 2025 | -7.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | -9.4% |
| Mar 2026 | -8.2% |
| Dec 2025 | -7.2% |
| Sep 2025 | -4.1% |
| Jun 2025 | -11.9% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SPAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | |
|---|---|---|---|
| Revenue | $606.7K | $2.2M | $917.7K |
| Gross profit | $202.2K | $906.1K | $311.1K |
| Operating income | -$14.5M | -$7.2M | -$6.3M |
| Net income | -$14.3M | -$7.4M | -$6.3M |
| EPS (diluted) | -0.85 | -0.70 | -0.79 |
| Operating cash flow | -$6.2M | -$4.1M | -$2.0M |
| Long-term debt | $146.0K | $146.0K | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SPAI Stock Sonar score 6/7 axes
Find similar shapesCompareSPAI ranks highest on risk and compliance (73rd percentile) and financial health (44th), and lowest on growth (4th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SPAI filings, in plain words
Are Safe Pro insiders buying or selling SPAI?
In the 180 days to 2026-10-28, Safe Pro insiders were net sellers, a net $4.0M across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Safe Pro insiders were net sellers of SPAI, a net $4.0M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $4.0M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
